Malaysia Automotive, Robotics and IoT Institute (MARii) and MKM Global Holdings Sdn Bhd signed a Memorandum of Understanding (MoU) to collaborate in the commercialisation of products and services related to high throughput diagnostics for communicable and non-communicable diseases within the members of Suruhanjaya Koperasi Malaysia (SKM).

The event also witnessed the appointment of MKM Global Holdings (a wholly-owned subsidiary of Institut Koperasi Malaysia) by RZAC ImmuneSAFE Sdn Bhd, as the exclusive sub-distributor through a reseller agreement signed between both parties.

Under the reseller agreement, the ImmuSAFE™ test kits will be promoted to 6,000,000 Suruhanjaya Koperasi Malaysia (SKM) members, marking another important milestone in its commercialisation since it was launched in September 2020.

There are a total of 14,668 co-operatives currently registered in Malaysia, with a turnover of RM45.7 billion in 2019, dropping to an estimated RM35 billion in 2020 due to COVID-19.

ImmuSAFETM is a lab-based, multi-antigen, multi-viral, fully qualitative and quantitative serology test, detecting the prevalence of antibodies in relation to 9 different domains of the SARS-CoV-2 virus.

The test results offer information on risk factors of infectiousness and presence of protective antibodies against COVID-19, in both symptomatic and asymptomatic individuals. This means information of prior infections and immunity from COVID-19 can be known to an individual from the ImmuSAFE™ test results.

A main beneficiary of this information are industry players and businesses, that are now able to better manage the impacts of health risks of employees towards their daily operations.

Under the Malaysia Co-operative Transformation Plan 2021-2025 (TransKom), the sector aims to contribute 5 percent of the country’s gross domestic product (GDP).

“This collaboration is a huge step forward in the use of home-grown technologies to allow businesses affected by the pandemic to better protect their lives and livelihoods”, said Dato’ Madani.

“The utilisation of this medical technology provides new options for the co-operatives sector to reach their business goals, despite challenges that remain ahead in managing the pandemic”, he added.

“We have faith in this partnership is in accordance with the plan of TransKoM which was recently launched by our Prime Minister. One of the thrusts is, creation of a sustainable business environment, and the empowerment of cooperative governing body and delivery system”, said Datuk Iskandar.

He added, this collaboration is timely with current situations and simultaneously benefits both the company and the society.

The MoU between MARii and MKM Global Holdings was signed by MARii CEO, Dato’ Madani Sahari, and Datuk Iskandar Datuk Abdul Malik, Executive Director of MKM Global Holdings.

The reseller agreement was signed between Dato’ Sri Rayyan Joseph King, Director of RZAC ImmuneSAFE and Datuk Iskandar Datuk Abdul Malik.

Also in attendance as witnesses were Datuk Phang Ah Tong (Chairman of MARii), Datuk Wira (Dr.) Rosli Mat Hassan (Chairman of MKM Global Holdings) and Datuk Wan Khalik Wan Muhammad (Director of RZAC ImmuneSAFE).